Brian Smith, MD
Urology · Salina, KSNPI 1952385817
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 176 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$624
- Astellas Pharma US Inc$292
- Dendreon Pharmaceuticals LLC$276
- AbbVie$237
- Urogen Pharma, Inc.$208
- 180 Medical, Inc.$169
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,28495%
- Education$1655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $624 |
| Astellas Pharma US Inc | 18 | $292 |
| Dendreon Pharmaceuticals LLC | 11 | $276 |
| AbbVie(2 entities) | 17 | $237 |
| Urogen Pharma, Inc. | 9 | $208 |
| 180 Medical, Inc. | 7 | $169 |
| Teleflex LLC | 7 | $142 |
| Pfizer | 7 | $134 |
| Endo Pharmaceuticals Inc. | 8 | $133 |
| Boston Scientific | 6 | $123 |
| Medtronic | 5 | $118 |
| Stryker | 2 | $85 |
| Axonics, Inc. | 5 | $84 |
| Ambu Inc. | 5 | $70 |
| Olympus America Inc. | 4 | $69 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| Procept Biorobotics Corporation | 3 | $62 |
| Neotract Inc. | 4 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Progenics Pharmaceuticals, Inc. | 2 | $49 |
| Vertex | 2 | $49 |
| Convatec Inc. | 1 | $41 |
| BD | 1 | $41 |
| Endo USA, Inc. | 2 | $39 |
| Tolmar Pharmaceuticals, Inc. | 2 | $37 |
| Myovant Sciences Inc. | 2 | $31 |
| Novartis | 1 | $25 |
| Bayer | 1 | $20 |
| Calyxo, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Organon | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Immunitybio, Inc. | 1 | $15 |
How this compares
$3,449 in reported general payments places this provider in the 55th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $166,430 |
| GemtesaVibegron | 49 | $33,600 |
| MyrbetriqMirabegron | 33 | $28,501 |
| Solifenacin Succinate | 131 | $8,654 |
| Tamsulosin Hcl | 809 | $8,078 |
| Oxybutynin Chloride ErOxybutynin Chloride | 355 | $6,986 |
| Finasteride | 715 | $6,316 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 22 | $4,484 |
| NitrofurantoinNitrofurantoin Macrocrystal | 78 | $2,909 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 45 | $1,749 |
| Bethanechol Chloride | 16 | $1,502 |
| Testosterone Cypionate | 35 | $1,234 |
| Methenamine Hippurate | 17 | $812 |
| Oxybutynin Chloride | 32 | $800 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $292 | $194,93157 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $33,60049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 urology providers in Kansas.
Other urology in Salina
- Ryan PayneSalina$12K
- Julianne RathbunSalina$6K
- Michael MatteucciSalina$3K
- William MauchSalina$2K
- Timothy RichardsonWichita$493K
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.